Cargando…

Assessment of Therapeutic Response of Edaravone and Riluzole Combination Therapy in Amyotrophic Lateral Sclerosis Patients

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a progressive disease characterized by chronic degeneration of upper and lower motor neurons and finally death within 3–5 years usually because of respiratory failure. Riluzole and edaravone are presently available treatments. It may be better to tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samadhiya, Swapnil, Sardana, Vijay, Bhushan, Bharat, Maheshwari, Dilip, Goyal, Ravi, Pankaj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540964/ https://www.ncbi.nlm.nih.gov/pubmed/36211189 http://dx.doi.org/10.4103/aian.aian_1083_21

Ejemplares similares

Propensity of Stroke in Standard versus Various Aortic Arch Variants: A 200 Patients Study
por: Samadhiya, Swapnil, et al.
Publicado: (2022)

In silico studies reveal structural deviations of mutant profilin-1 and interaction with riluzole and edaravone in amyotrophic lateral sclerosis
por: Sadr, Ahmad Shahir, et al.
Publicado: (2021)

Riluzole and Edavarone: The Hope Against Amyotrophic Lateral Sclerosis
por: Rokade, Aditi V, et al.
Publicado: (2022)

Adherence to riluzole in patients with amyotrophic lateral sclerosis: an observational study
por: Introna, Alessandro, et al.
Publicado: (2018)

Riluzole is associated with decreasing neuritic plaque severity in amyotrophic lateral sclerosis
por: Mazumder, Srestha, et al.
Publicado: (2022)

Ethnical Disparities in Response to Edaravone in Patients With Amyotrophic Lateral Sclerosis
por: Jayasinghe, Maleesha, et al.
Publicado: (2022)

Riluzole prescribing, uptake and treatment discontinuation in people with amyotrophic lateral sclerosis in Scotland
por: Jayaprakash, Kiran, et al.
Publicado: (2020)

Administration of Riluzole Oral Suspension During the Different Stages of Amyotrophic Lateral Sclerosis
por: Povedano Panades, Mónica, et al.
Publicado: (2021)

Early initiation of riluzole may improve absolute survival in amyotrophic lateral sclerosis
por: Thakore, Nimish J., et al.
Publicado: (2022)

Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis
por: Okada, Masamitsu, et al.
Publicado: (2018)

Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients
por: Park, Jin-Mo, et al.
Publicado: (2019)

Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis
por: Cho, HaEun, et al.
Publicado: (2020)

Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19
por: Al-Chalabi, Ammar, et al.
Publicado: (2021)

A Randomized, Double Blind, Placebo-Controlled Trial of Pioglitazone in Combination with Riluzole in Amyotrophic Lateral Sclerosis
por: Dupuis, Luc, et al.
Publicado: (2012)

Riluzole Selective Antioxidant Effects in Cell Models Expressing Amyotrophic Lateral Sclerosis Endophenotypes
por: Sala, Gessica, et al.
Publicado: (2019)

Dysphagia in Amyotrophic Lateral Sclerosis: Impact on Patient Behavior, Diet Adaptation, and Riluzole Management
por: Onesti, Emanuela, et al.
Publicado: (2017)

Repeated neurofilament light chain measurements did not capture Riluzole therapeutic effect in amyotrophic lateral sclerosis patients
por: Esselin, Florence, et al.
Publicado: (2022)

How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?
por: Watanabe, Kazutoshi, et al.
Publicado: (2018)

Renal function in amyotrophic lateral sclerosis patients on long-term treatment with edaravone
por: Kakimoto, Asako, et al.
Publicado: (2021)

Partial Block by Riluzole of Muscle Sodium Channels in Myotubes from Amyotrophic Lateral Sclerosis Patients
por: Deflorio, Cristina, et al.
Publicado: (2014)

Riluzole–Rasagiline Hybrids: Toward the Development of Multi-Target-Directed Ligands for Amyotrophic Lateral Sclerosis
por: Albertini, Claudia, et al.
Publicado: (2022)

Magnetic resonance metrics to evaluate the effect of therapy in amyotrophic lateral sclerosis: the experience with edaravone
por: Distaso, Eugenio, et al.
Publicado: (2021)

Investigating Edaravone Use for Management of Amyotrophic Lateral Sclerosis (ALS): A Narrative Review
por: Neupane, Purushottam, et al.
Publicado: (2023)

Riluzole 5 mg/mL oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis
por: Dyer, Ann Margaret, et al.
Publicado: (2016)

Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System
por: Vu, Michelle, et al.
Publicado: (2020)

Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone
por: Han, Hee Jo, et al.
Publicado: (2022)

Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection
por: Cha, Sun Joo, et al.
Publicado: (2022)

Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis
por: Nourelden, Anas Zakarya, et al.
Publicado: (2023)

Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis
por: Hinchcliffe, Michael, et al.
Publicado: (2017)

From Riluzole to Dexpramipexole via Substituted-Benzothiazole Derivatives for Amyotrophic Lateral Sclerosis Disease Treatment: Case Studies
por: Mignani, Serge, et al.
Publicado: (2020)

Functional connectivity–based prediction of global cognition and motor function in riluzole-naive amyotrophic lateral sclerosis patients
por: Wei, Luqing, et al.
Publicado: (2022)

Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design
por: Berry, James, et al.
Publicado: (2021)

Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study
por: Park, Jin-Mo, et al.
Publicado: (2022)

Interstitial pneumonia and other adverse events in riluzole-administered amyotrophic lateral sclerosis patients: a retrospective observational study
por: Inoue-Shibui, Aya, et al.
Publicado: (2019)

Post-Marketing Experience of Edaravone in Amyotrophic Lateral Sclerosis: A Clinical Perspective and Comparison With the Clinical Trials of the Drug
por: Ortiz, Juan Fernando, et al.
Publicado: (2020)

Role of Surgical Procedures (VP Shunt and ETV) in Tuberculous Meningitis with Hydrocephalus (TBMH): A Systematic Review
por: Bhushan, Bharat, et al.
Publicado: (2021)

Long‐term edaravone efficacy in amyotrophic lateral sclerosis: Post‐hoc analyses of Study 19 (MCI186‐19)
por: Shefner, Jeremy, et al.
Publicado: (2019)

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment
por: Genge, Angela, et al.
Publicado: (2022)

Spinal cord and brain concentrations of riluzole after oral and intrathecal administration: A potential new treatment route for amyotrophic lateral sclerosis
por: Keifer, Orion P., et al.
Publicado: (2023)

“Huoling Shengji granule” for amyotrophic lateral sclerosis: protocol for a multicenter, randomized, double-blind, riluzole parallel controlled clinical trial
por: Liu, Xiaolu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_13alblpcn467jlt6p4a55nu5ah